Table 3 Percentage of adverse effects experienced by participants across the studies reviewed
Source | Year | Number of patients enrolled | Breast discomfort % (n) | Nausea % (n) | Irritability % (n) | Headaches % (n) | Breakthrough bleeding % (n) | Weight gain % (n) | Decreased Libido % (n) | Depression % (n) | Vaginal dryness % (n) | Acne % (n) | Hair Loss % (n) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Petraglia et al. | 2012 | 168 | 4.2 (7) | 3 (5) | 2.4 (4) | Â | Â | Â | Â | Â | Â | Â | Â |
Morotti et al. | 2014 | 25 | 4 (1) | 8 (2) | Â | 16 (4) | 20 (5) | 8 (2) | 4 (1) | Â | Â | Â | Â |
Morotti et al. | 2017 | 103 | Â | Â | Â | 8.7 (9) | 23.3 (24) | 30.1 (31) | 10.7 (11) | 6.8 (7) | Â | 4.8 (5) | Â |
Maiorana et al. | 2017 | 132 | 8.1 (11) | Â | Â | 3.6 (5) | 42.3 (56) | 17.1 (23) | 8.1 (11) | 16.2 (22) | 3.6 (5) | Â | Â |
Römer | 2018 | 37 |  |  |  | 10.8 (4) | 18.9 (7) |  |  | 10.8 (4) |  |  |  |
Vercellini et al. | 2018 | 153 | 0.65 (1) | 0.65 (1) | Â | 4.5 (7) | 3.9 (6) | 2.6 (4) | 0.65 (1) | Â | 0.65 (1) | 1.3 (2) | Â |
Sansone et al. | 2018 | 25 | Â | Â | Â | Â | Â | 12.5 (3) | Â | Â | Â | Â | Â |
Lang et al. | 2018 | 255 | Â | Â | Â | Â | 7.9 (20) | Â | Â | Â | Â | Â | Â |
Yu et al. | 2019 | 220 | 1.8 (4) | Â | Â | 0 (0) | 1.8 (4) | Â | Â | Â | Â | Â | Â |
Del Forno et al. | 2019 | 69 | 1.4 (1) | 0 (0) | 1.4 (1) | 2.9 (2) | 8.7 (6) | 14.5 (10) | 7.2 (5) | Â | 7.2 (5) | 1.4 (1) | 2.9 (2) |
66 | 7.6 (5) | 0 (0) | 7.6 (5) | 3 (2) | 21.2 (14) | 30.3 (20) | 18.2 (12) | Â | 10.6 (7) | 1.5 (1) | 0 | ||
Ferrero et al. | 2020 | 44 | Â | Â | Â | 23.3 (10) | Â | Â | Â | Â | Â | 7 (3) | Â |
Cho et al. | 2020 | 3356 | 1.25 (42) | 0.64 (22) | Â | 1.32 (45) | 4.18 (141) | 2.6 (88) | Â | 0.77 (26) | Â | 0.77 (26) | 0.32 (11) |
Barra et al. | 2020 | 83 | Â | Â | Â | 21.2 (18) | 26.9 (23) | 30.1 (25) | 2.8 (3) | 9.6 (8) | Â | 1.9 (2) | Â |
Margatho et al. | 2020 | 103 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Nirgianakis et al. | 2020 | 130 | 15 (20) | Â | Â | 8 (11) | 31 (40) | 20 (26) | 19 (25) | 33 (43) | Â | 10 (13) | 6 (8) |
Kitawaki et al. | 2021 | 59 | Â | Â | Â | Â | 5.1 (3) | Â | Â | Â | Â | Â | Â |